Adimmune Corporation

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.adimmune.com.tw

Country

Taiwan

Exchange

Taiwan

Taichung, Taiwan

Adimmune provides the development, manufacture, and distribution of vaccines and other biological products globally. The company offers AdimFlu-S, a quadrivalent influenza vaccine.

Its portfolio also includes suspensions for injection influenza vaccines, and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19.

Its portfolio also includes H5N1 vaccine, and cell culture-derived Japanese encephalitis vaccine. Incorporated in 1965 and headquartered in Taichung, Taiwan, Adimmune was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. before rebranding in 2001.

Key Stats

52-Week Range

NT$16.40NT$22.50

Beta0.27

Trailing P/EN/A

Forward P/E4.91

Trailing EPS-0.57

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.